-- FY 07 revenues grow 75% to $42.1 million
-- FY 07 earnings up 43% to $6.9 million or 50 cents per diluted share
GUANGZHOU, China, March 27 /Xinhua-PRNewswire/ -- China Medicine Corporation (OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), a leading distributor and developer of prescription and over the counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary-supplements, medical devices, and medical formulations in the PRC, today reported record financial results for the fourth quarter and fiscal year ended December 31, 2007.
Fourth Quarter 2007 Highlights
-- Revenues increased 89% from Q4 of 2006, to $16.2 million
-- Gross profit increased 30% from Q4 of 2006, to $4.5 million
-- Operating income increased 15% from Q4 of 2006, to $3.4 million
-- Net Income increased 15% from Q4 of 2006, to $2.8 million
Full Year 2007 Highlights
-- Total revenues increased 75% to $42.1 million
-- Gross profit increased 38% to $12.4 million
-- Operating income increased 36% to $8.4 million
-- Net income increased 43% to $6.9 million, or $0.50 per diluted share
-- Obtained regional distribution rights to 774 new products in
Guangdong Province
-- Received RMB 800,000 in grants for aflatoxin detoxifizyme ("ADTZ")
project from Education Department of Guangdong Province
"This was a very successful year for China Medicine, both in terms of financial performance and the execution of our business strategy. Our very strong revenue growth was driven by an expanded number of pharmaceutical products provided by our suppliers, as well as increased sales of our self-developed medical formulations and other intellectual property relating to pharmaceutical product development," said Mr. Senshan Yang, China Medicine’s Chairman and CEO.
"In 2007, we expanded our distribution network to cover both municipal and rural areas of Guangdong Province in China, to support the Chinese government’s recent policy to promote healthcare coverage among the rural and low-income population. In the short term, our expansion to cover these new markets resulted in a reduction in our gross margins as we increased sales of lower-cost over-the-counter pharmaceutical and TCM products. However, as spending on rural healthcare continues to increase, we believe that the rural markets have tremendous potential as increasing funding and an aging population drive demand for more advanced pharmaceutical products."
Fourth Quarter 2007 Results
China Medicine’s total revenues in the fourth quarter were $16.2 million, an increase of 89% over the fourth quarter of 2006. This was attributed to a 112% increase in product sales, primarily driven by the increase in over-the-counter product sales made through the company’s newly expanded distribution network to municipal and rural areas of Guangdong Province. Product sales totaled $14.7 million and accounted for 91% of total net revenues. Sales of prescription products accounted for 59%, and over-the-counter medicines accounted for 31%, of total revenues during the quarter. Medical formula sales accounted for the remaining 9% of total revenues, totaling $1.5 million, down 10% from the same quarter of 2006. This decline was due to stricter regulation by the State Food and Drug Administration, which must approve every transfer of ownership of a medical formula in China, and which recently increased the complexity of its approval process.
Gross profit in the fourth quarter of 2007 was $4.5 million, an increase of 30% over the fourth quarter of 2006. Gross margin was 28% of total revenues, down from 40% of total revenues in the fourth quarter of 2006. The decline in gross margin was due to higher sales of over-the-counter products, which have lower profit margins than prescription products, and the costs of expansion of the Company’s distribution network to rural areas of China in 2007.
Operating expenses in the fourth quarter of 2007 were $1.1 million, up 120% from $0.5 million in the fourth quarter of 2006. This increase was due to higher selling, general and administrative expenses caused by increased public company expenses, higher salaries and employee sales bonuses, as well as the amortization of non-cash expenses from incentive options, increased advertising, trade-show and marketing expenses, and the costs of setting up a distribution network to cover the rural areas of Guangdong Province. The Company does not expect significant increases in selling, general and administrative expenses over the next several quarters.
Operating expenses represented 7% of total revenues in the fourth quarter of 2007, up from 6% in the fourth quarter of 2006.
The Company recorded $214,541 in research and development expenses in the fourth quarter of 2007, compared to $23,378 in the fourth quarter of 2006. The significant increase was primarily due to the pre-clinical study of Yutian Capsule, a traditional Chinese medicine designed for use in the treatment of lung cancer.
Operating income was $3.4 million in the fourth quarter of 2007, up 15% from $2.9 million in fourth quarter of 2006. Operating margin was 21%, as compared to 34% a year ago.
Net income for the fourth quarter of 2007 was $2.8 million, or $0.17 per diluted share, compared to $2.4 million, or $0.31 per diluted share in the fourth quarter of 2006. Earnings per share reflect an additional 8.2 million diluted weighted average shares, primarily due to the exercise of warrants and options in 2007, which generated $7.8 million in gross proceeds to the Company.
Full Year 2007 Results
For the full year 2007, total revenues were $42.1 million, up 75% from $24.0 million in 2006. Approximately 93% of revenue came from product sales and 7% came from medical formula sales. Gross profit for the full year 2007 was $12.4 million, an increase of 38% from $9.0 million in 2006. Gross profit margin was 29% in 2007, a decrease from 37% in 2006. Operating income was $8.4 million, up 36% from $6.2 million in 2006. Operating margin was 20%, as compared to 26% in 2006. Net income for 2007 was $6.9 million or $0.50 per diluted share, compared to $4.8 million or $0.63 per diluted share in 2006. Earnings per share reflect an additional 6.0 million diluted weighted average shares, primarily due to the exercise of warrants and options in 2007.
Financial Condition
As of December 31, 2007, China Medicine had $5.8 million in cash and cash equivalents, and approximately $28.5 million in working capital, an increase of 140% from $11.9 million in 2006. For the year ended December 31, 2007, China Medicine used $2.3 million in cash from operations, due to the increase of advances to suppliers and inventories required to support higher sales. China Medicine also received $7.8 million in proceeds from the exercise of warrants and options. Stockholders’ equity as of December 31, 2007 was $30.8 million, an increase of 132% over the $13.3 million recorded as of December 31, 2006.
2008 Outlook
"During 2008 we expect to see continued solid growth in sales, along with improving margins as we leverage our expanded distribution footprint, expand sales of higher margin exclusive products, and see a growing contribution from sales of our proprietary medical formulations," said Mr. Yang. "We are very encouraged by the contribution of our R&D partnerships to building a strong new product pipeline, and expect to report significant clinical milestones over the course of 2008. We are also focused on moving our novel ADTZ product into commercialization this year, and expect to obtain our production permit for the treatment of animal feed and begin trial sales in 2008. If we are successful, this would set us up to begin recognizing meaningful revenues from ADTZ in 2009 and could be an important driver for the Company’s future growth. Finally, China Medicine continues to evaluate opportunities to acquire a pharmaceutical manufacturing facility to strengthen our competitive position and achieve vertical integration for our proprietary products, while enhancing our overall profitability," concluded Mr. Yang.
Based on China Medicine’s expectations of continued strong demand in the pharmaceutical market, the company expects to achieve revenue growth in the range of approximately 25-35%, gross margins in the range of 30-35%, and approximately 20-22% growth in net income for the full year of 2008.
Conference Call
China Medicine will hold its fourth quarter conference call for all interested persons at 9:00 a.m. Eastern Time on March 27, 2008 to discuss its results. To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 888-419-5570. International callers should dial 617-896-9871. When prompted by the operator, mention conference passcode 25022850. If you are unable to participate in the call at its scheduled time, a replay will be available for seven days starting on Thursday, March 27 at 11:00 a.m. Eastern Time. To access the replay, dial 888-286-8010 (international callers dial 617-801-6888), and enter the passcode 92139283.
About China Medicine Corporation
China Medicine Corporation is a leading pharmaceutical company which discovers and develops medical formulations and distributes over 2,200 pharmaceutical products in China including prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements. The Company distributes the products to wholesale distributors in 28 provinces, more than 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for many uses including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company’s website at http://www.chinamedicinecorp.com .
Cautionary Statement
This press release contains forward-looking statements concerning the Company’s business and products. The Company’s actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risks factors detailed in the Company’s reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
- FINANCIAL TABLES FOLLOW -
CHINA MEDICINE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME
FOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006
Three months ended Twelve Months ended
December 31, December 31,
2007 2006 2007 2006
REVENUES
Product sales 14,694,861 6,916,225 39,247,130 20,772,783
Medical formula sales 1,464,625 1,630,031 2,858,257 3,219,167
Total revenues 16,159,486 8,546,256 42,105,387 23,991,950
COST OF GOOD SOLD 11,678,186 5,106,769 29,708,088 15,017,100
GROSS PROFIT 4,481,300 3,439,487 12,397,299 8,974,850
OPERATING EXPENSES
Research and development 214,541 23,378 651,990 294,080
Selling, general and
administrative 895,619 481,094 3,343,058 1,565,288
Reverse acquisition -- 931,270
Total operating
expenses 1,110,160 504,472 3,995,048 2,790,638
INCOME FROM OPERATIONS 3,371,140 2,935,015 8,402,251 6,184,212
OTHER INCOME (EXPENSE), NET 11,819 (56,189) 15,423 (199,945)
INCOME BEFORE INCOME TAXES 3,382,959 2,878,827 8,417,674 5,984,267
AND MINORITY INTEREST
PROVISION FOR INCOME TAXES 630,371 499,857 1,649,114 1,229,688
INCOME BEFORE MINORITY
INTEREST 2,752,588 2,378,970 6,768,560 4,754,579
MINORITY INTEREST 26,012 33,295 94,658 33,295
NET INCOME 2,778,600 2,412,265 6,863,218 4,787,874
OTHER COMPREHENSIVE INCOME
Foreign currency
translation adjustment 721,233 200,151 1,621,672 399,991
COMPREHENSIVE INCOME 3,499,833 2,612,416 8,484,890 5,187,865
Earning per share - basic $ 0.19 $ 0.32 $ 0.56 $ 0.65
Earning per share - diluted $ 0.17 $ 0.31 $ 0.50 $ 0.63
Weighted average number of
shares outstanding - basic 14,688,310 7,635,111 12,346,208 7,352,082
Weighted average number of
shares outstanding -
diluted 15,890,110 7,788,000 13,658,007 7,653,584
CHINA MEDICINE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
AS OF DECEMBER 31, 2007 AND 2006
A S S E T S
2007 2006
CURRENT ASSETS
Cash $5,767,774 $371,480
Accounts receivable, trade, net of
allowance for doubtful accounts
of $55,640 and $34,021 as of
December 31, 2007 and
December 31, 2006, respectively 13,626,347 7,034,911
Inventories 3,948,460 1,900,467
Advances to suppliers 5,983,277 3,126,100
Other current assets 81,221 42,136
Total current assets 29,407,079 12,475,094
EQUIPMENT, net 1,388,919 1,215,311
OTHER ASSETS
Deferred expenses 678,237 951,312
Intangible assets, net 1,166,003 128,882
Total other assets 1,844,240 1,080,194
Total assets $32,640,238 $14,770,599
L I A B I L I T I E S A N D S H A R E H O L D E R S’ E Q U I T Y
CURRENT LIABILITIES
Accounts payable, trade $76,907 $188,877
Other payables - related parties -- 30,000
Other payables and accrued
liabilities 70,343 23,265
Customer deposits 203,281 17,980
Taxes payable 468,184 295,902
Liquidated damages payable 44,003 44,003
Total liabilities 862,718 600,027
MINORITY INTEREST 893,337 908,480
SHAREHOLDERS’ EQUITY
Preferred stock, $0.0001 par value;
10,000,000 shares authorized,
111,649 and 2,340,000 shares
issued and outstanding
at December 31, 2007 and 2006,
respectively 11 234
Common stock, $0.0001 par value;
100,000,000 shares authorized,
14,821,641 and 8,160,000 shares
issued and outstanding
at December 31, 2007 and 2006,
respectively 1,482 816
Paid-in capital 12,560,078 4,396,971
Contribution receivable -- (961,500)
Statutory reserves 2,191,230 1,345,206
Retained earnings 14,008,587 7,979,242
Accumulated other comprehensive
income 2,122,795 501,123
Total shareholders’ equity 30,884,183 13,262,092
Total liabilities and
shareholders’ equity $32,640,238 $14,770,599
CHINA MEDICINE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006
2007 2006
CASH FLOWS FROM OPERATING
ACTIVITIES:
Net income $6,875,369 $4,787,874
Adjustments to reconcile net income
to cash
used in operating activities:
Minority interest (94,658) (33,295)
Depreciation and amortization 303,957 162,051
Bad debt expenses 18,495 --
Loss on sale of assets -- 15,732
Stock issued for services 179,400 607,500
Amortization of stock option
compensation 154,470 86,521
Amortization of deferred expenses 325,687 --
Loss from investment -- 110,982
Change in operating assets and
liabilities
Accounts receivable, trade (5,879,829) (4,514,763)
Inventories (1,840,170) (498,624)
Advances to suppliers (2,535,589) (2,933,832)
Other current assets (34,728) (129,096)
Accounts payable, trade (120,129) 17,275
Other payables - related parties (30,000) 30,000
Other payables and accrued
liabilities 45,119 (73,246)
Customer deposits 176,763 (19,140)
Taxes payable 145,730 121,850
Liquidated damages payable -- 44,003
Net cash used in operating
activities (2,310,113) (2,218,208)
CASH FLOWS FROM INVESTING
ACTIVITIES:
Purchase of equipment (389,588) (825,787)
Purchase of intangible asset -- (703)
Net cash used in investing
activities (389,588) (826,490)
CASH FLOWS FROM FINANCING
ACTIVITIES:
Payments on short-term loans -- (94,094)
Proceeds from issuance of preferred
stock -- 3,783,000
Payments for reverse acquisition -- (32,398)
Proceeds from exercise of warrants
and options 7,829,681 --
Cash paid on shares redeemed -- (167,602)
Net cash provided by financing
activities 7,829,681 3,488,906
EFFECT OF EXCHANGE RATE ON CASH 266,313 (164,692)
INCREASE IN CASH 5,396,293 279,516
CASH, beginning of year 371,480 91,964
CASH, end of year $5,767,773 $371,480
For more information, please contact:
Company Contact:
Ms. Huizhen Yu
Chief Financial Officer
China Medicine Corp
Tel: +86-20-8739-1718
Email: konzern08@163.com
Investor Relations Contact:
Mr. Crocker Coulson
President
CCG Elite Investor Relations
Tel: +1-646-213-1915 (NY Office)
Email: crocker.coulson@ccgir.com
